Trials
Search / Trial NCT06442891

Self-Administered Relaxing Acupressure to Reduce Fatigue in Adolescent and Young Adult Cancer Survivors

Launched by UNIVERSITY OF MICHIGAN ROGEL CANCER CENTER · May 30, 2024

Trial Information

Current as of February 08, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is exploring whether self-administered relaxing acupressure can help reduce fatigue in adolescent and young adult cancer survivors. Acupressure involves applying gentle pressure to specific points on the body, similar to massage, and has been shown to help alleviate fatigue in adult cancer patients. The researchers want to see if this method can also benefit younger survivors who are experiencing fatigue after their cancer treatments.

To be eligible for the study, participants must be between 15 and 39 years old, at least three months past their cancer treatment, and currently experiencing significant fatigue. They should also be able to read and speak English and have completed their cancer treatment within the last five years. Unfortunately, individuals with certain medical conditions or those who have recently received acupressure or acupuncture are not eligible. If you choose to participate, you will learn how to perform acupressure on yourself, and the study aims to see how effective this technique is in helping you feel less tired.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 15 - 39 years old
  • At least three months post cancer treatment (e.g., surgery, radiation or chemotherapy). Participants receiving maintenance hormonal or targeted therapies will be allowed to enroll as determined by the study investigator
  • Report clinically relevant fatigue in the past seven days (Patient Reported Outcomes Measurement Information Systems \[PROMIS\] Fatigue 4a scores ≥ 55)
  • Speak / read English
  • CRF started at or after the diagnosis of cancer
  • Completed cancer treatment within the past five years
  • Exclusion Criteria:
  • Diagnosis of untreated anemia, mood disorder, or hypothyroidism
  • Plan to begin new pharmacological, psychological, or other treatments (i.e., physical therapy or dietary supplements) for CRF during the study. Although, participants may continue usual treatments for CRF if the treatments were initiated at least eight weeks prior to study enrollment, and the dose has not changed
  • Plan to become pregnant or lactating during the study period
  • Received acupressure or acupuncture in the past year

Trial Officials

Robert Knoerl

Principal Investigator

University of Michigan Rogel Cancer Center

About University Of Michigan Rogel Cancer Center

The University of Michigan Rogel Cancer Center is a leading academic research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials. As a National Cancer Institute-designated Comprehensive Cancer Center, it combines cutting-edge research, state-of-the-art facilities, and a multidisciplinary team of experts to deliver personalized care and foster groundbreaking discoveries. The center's commitment to improving patient outcomes is reflected in its robust portfolio of clinical trials, which explore novel therapies and enhance understanding of cancer biology. Through collaboration with patients, researchers, and healthcare professionals, the Rogel Cancer Center aims to translate scientific insights into transformative therapies, ultimately contributing to the global fight against cancer.

Locations

Ann Arbor, Michigan, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0